Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024
與 Theía Open Innovation 合作進行的 KIO-301 治療色素性視網膜炎的 2 期試驗,預計將於 2024 年第四季度啓動
Phase 2 clinical trial for KIO-104 for retinal inflammation expected to begin in 2025
KIO-104 視網膜炎症的 2 期臨床試驗預計將於 2025 年開始
Ended Q1 2024 with $31.3 million in cash and cash equivalents, providing an expected runway of more than two years
截至2024年第一季度,現金及現金等價物爲3,130萬美元,預計將持續兩年以上
Encinitas, California--(Newsfile Corp. - May 10, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announces first quarter 2024 financial results and updates on its development pipeline of treatments for retinal disease.
加利福尼亞州恩西尼塔斯--(Newsfile Corp.,2024年5月10日)——Kiora Pharmicals, Inc.(納斯達克股票代碼:KPRX)(“Kiora” 或 “公司”)公佈了2024年第一季度財務業績及其視網膜疾病治療藥物研發管道的最新情況。
"Our balance sheet and strategic partnership with Théa Open Innovation (TOI) put us in a strong position to advance our two retinal programs, KIO-301 and KIO-104, into mid-stage clinical trials," said Brian M. Strem, Ph.D., chief executive officer of Kiora. "Both compounds, given their mechanisms of action, have the potential to address multiple diseases; KIO-301 for the treatment of inherited retinal disorders, and KIO-104 for the treatment of retinal inflammatory diseases. Our upcoming Phase 2 ABACUS-2 trial of KIO-301 for the treatment of retinitis pigmentosa, is a multi-center double-masked, randomized, controlled, multiple-dose study performed in collaboration with TOI.
“我們的資產負債表和與 Th 的戰略合作伙伴關係e開放創新(TOI)使我們處於有利地位,可以將我們的兩個視網膜項目 KIO-301 和 KIO-104 推進到中期臨床試驗。” Kiora首席執行官布萊恩·斯特雷姆博士說。“鑑於其作用機制,這兩種化合物都有可能治療多種疾病;KIO-301 用於治療遺傳性視網膜疾病,KIO-104 用於治療視網膜炎性疾病。我們即將推出的用於治療色素性視網膜炎的 KIO-301 二期 ABACUS-2 試驗是一項與 TOI 合作進行的多中心雙面罩、隨機、對照、多劑量研究。
"As part of our partnership, TOI will fund the remaining clinical development of KIO-301 across multiple indications, allowing us to efficiently invest our capital in the development of KIO-104 to treat retinal inflammatory diseases. KIO-104 may address the established need for eye treatments that spare the complications of chronic steroid use and/or systemic anti-inflammatory drugs. Clinical proof-of-concept for KIO-104 in the treatment of non-infectious uveitis, a rare retinal inflammatory condition, has been established with recently published results from a Phase 1/2a study. Prior to initiating a Phase 2 trial, we are conducting additional investigational new drug (IND) enabling work. Beyond non-infectious uveitis, the mechanism of action of KIO-104 could apply to other retinal conditions, such as macular edema, and proliferative vitreoretinopathy (PVR), a serious complication following retinal detachment repair."
“作爲我們合作的一部分,TOI 將爲多種適應症的 KIO-301 剩餘臨床開發提供資金,使我們能夠有效地將資金投資於用於治療視網膜炎性疾病的 KIO-104 的開發。KIO-104 可以滿足眼部治療的既定需求,以避免長期使用類固醇和/或全身性消炎藥引起的併發症。根據最近公佈的 1/2a 期研究結果,KIO-104 用於治療非感染性葡萄膜炎(一種罕見的視網膜炎性疾病)的臨床概念驗證已經建立。在啓動2期試驗之前,我們正在開展其他研究性新藥(IND)支持工作。除非感染性葡萄膜炎外,KIO-104 的作用機制還可能適用於其他視網膜疾病,例如黃斑水腫和增生性玻璃體視網膜病變 (PVR),這是視網膜脫離修復後的嚴重併發症。”
"In the first quarter, we executed a strategic partnership with TOI, which included a $16 million upfront payment, and raised $15 million from an equity offering," added Melissa Tosca, EVP Finance. "These developments substantially strengthened our cash position, allowing us to advance our two exciting programs while maintaining G&A expenses, and provides a runway of greater than two years. The TOI upfront payment was recognized entirely in the first quarter as collaboration revenue and we expect future development and regulatory milestone payments to be treated similarly."
財務執行副總裁梅利莎·托斯卡補充說:“在第一季度,我們與TOI建立了戰略合作伙伴關係,其中包括1,600萬美元的預付款,並通過股票發行籌集了1500萬美元。”“這些事態發展極大地增強了我們的現金狀況,使我們能夠在維持併購費用的同時推進兩項激動人心的項目,並提供了兩年以上的延期。TOI預付款在第一季度被完全確認爲合作收入,我們預計未來的發展和監管里程碑付款將得到同樣的待遇。”
Milestones achieved in the first quarter and year-to-date 2024 include the following:
在第一季度和2024年迄今取得的里程碑包括以下內容:
KIO-301
KIO-301
Entered a strategic partnership granting TOI exclusive worldwide co-development and commercialization rights, excluding Asia, to KIO-301 for the treatment of retinal degenerative diseases. Under the terms of the agreement, Kiora received an upfront payment of $16 million, recognized as collaboration revenue, and is eligible to receive up to an additional $285 million in development, regulatory, and commercial milestones; tiered royalties of up to low 20 percent on net sales; and full reimbursement of future KIO-301 research and development expenses.
Reported quantitative functional MRI results at the Association of Research in Vision and Ophthalmology (ARVO) annual conference from ABACUS-1, showing a statistically significant increase in neural activity over baseline specifically within the brain's visual processing center. This increase in observed brain activity was time-dependent and concordant with previously reported improvements in visual field, visual acuity, and functional vision.
建立戰略合作伙伴關係,授予 TOI 在全球範圍內獨家的聯合開發和商業化權,不包括亞洲,用於治療視網膜退行性疾病。KIO-301根據協議條款,Kiora 收到了 1,600 萬美元的預付款,確認爲合作收入,並有資格額外獲得高達 2.85 億美元的開發、監管和商業里程碑;分級特許權使用費不超過淨銷售額的 20%;以及未來的 KIO-301 研發費用全額報銷。
在 ABACUS-1 視覺與眼科學研究協會(ARVO)年會上報告了定量功能磁共振成像結果,顯示神經活動比基線顯著增加,特別是在大腦的視覺處理中心。觀測到的大腦活動的增加是時間相關的,與先前報告的視野、視力和功能性視覺的改善一致。
KIO-104
KIO-104
Publication of results from a Phase 1 double-masked study of KIO-101 in the medical journal Pharmaceutics, documenting a 12-day treatment of KIO-101 topically at multiple doses was well tolerated in healthy volunteers and patients with inflammation of the eye. There was a significant decrease in conjunctival hyperemia in the treatment group compared to placebo.
Initiated Investigational New Drug enabling preclinical work in support of planned phase 2 retinal inflammation clinical trial.
在醫學雜誌上發表 KIO-101 的 1 期雙面研究結果 藥學, 記錄了爲期 12 天的局部多劑量治療 KIO-101,健康志願者和眼部發炎患者的耐受性良好。與安慰劑相比,治療組的結膜充血明顯減少。
啓動研究性新藥,支持計劃中的2期視網膜炎症臨床試驗的臨床前工作。
Kiora anticipates achieving the following clinical and regulatory milestones:
Kiora預計將實現以下臨床和監管里程碑:
KIO-301 • Type D meeting with the FDA for functional vision endpoint • Initiate ABACUS-2 clinical trial • Begin design of additional inherited retinal disease studies |
1H 2024 2H 2024 1H 2025 |
KIO-104 • Complete non-clinical package • Initiate Phase 2 clinical trial |
2H 2024 1H 2025 |
KIO-301 • D 型與 FDA 會面討論功能視覺終點 • 啓動 ABACUS-2 臨床試驗 • 開始設計其他遺傳性視網膜疾病研究 |
2024 年 1 小時 2024 年 2 小時 2025 年 1 小時 |
KIO-104 • 完整的非臨床套餐 • 啓動 2 期臨床試驗 |
2024 年 2 小時 2025 年 1 小時 |
Financial Results Highlights
財務業績亮點
Kiora ended the first quarter of 2024 with $31.3 million in cash and cash equivalents plus $1.8 million in research and development incentive tax credits and $0.2 million in collaboration receivables from TOI.
Kiora在2024年第一季度結束時獲得了3,130萬美元的現金和現金等價物,外加180萬美元的研發激勵稅收抵免和來自TOI的20萬美元合作應收賬款。
Revenue was $16.0 million for the first quarter of 2024, compared to no revenue in the first quarter of 2023. The revenue comes from collaboration revenue as part of an upfront payment from TOI connected to the strategic development and commercialization partnership.
2024年第一季度的收入爲1,600萬美元,而2023年第一季度沒有收入。收入來自合作收入,這是TOI與戰略發展和商業化合作夥伴關係相關的預付款的一部分。
Research and development expenses were $1.5 million, net of $0.2 million in offsetting credits related to expenses for KIO-301 which will be reimbursed by TOI, for the first quarter of 2024, compared to $0.4 million, net of $0.3 million in offsetting tax credits, for the first quarter of 2023. The increase was primarily due to a one-time licensing payment made to the University of California related to a sublicense fee of $0.7 million, and a decrease of $0.3 million in R&D tax credits due to reduced credit-eligible expenses given the KIO-301 expenses are now being reimbursed by TOI.
2024年第一季度的研發費用爲150萬美元,扣除與TOI將報銷的 KIO-301 費用相關的20萬美元抵消抵免,而2023年第一季度的研發費用爲40萬美元,扣除30萬美元的抵消性稅收抵免。增長的主要原因是向加州大學一次性支付了與70萬美元的分許可費相關的許可費,以及由於 TOI 現在報銷 KIO-301 費用,減少了30萬美元的研發稅收抵免,這是由於符合抵免條件的支出減少了。
General and administrative expenses were $1.3 million for the first quarter of 2024, compared to $1.3 million for the first quarter of 2023.
2024年第一季度的一般和管理費用爲130萬美元,而2023年第一季度爲130萬美元。
Net income was $13.5 million for the first quarter of 2024 compared to a net loss of $1.9 million for the first quarter of 2023. The change in income is attributable to the recognition of $16 million in collaboration revenue.
2024年第一季度的淨收入爲1,350萬美元,而2023年第一季度的淨虧損爲190萬美元。收入的變化歸因於1,600萬美元的合作收入的確認。
About Kiora Pharmaceuticals
關於 Kiora 製藥
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase. In addition to news releases and SEC filings, we expect to post information on our website, , and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Kiora Pharmaceuticals是一家臨床階段的生物技術公司,正在開發和商業化治療孤兒視網膜疾病的產品。KIO-301 正在開發用於治療色素性視網膜炎、脈絡膜血癥和斯塔加特病。它是一種分子光電開關,有可能恢復遺傳性和/或年齡相關性視網膜變性患者的視力。KIO-104 正在開發用於治療後部非感染性葡萄膜炎。它是二氫乳清酸脫氫酶的下一代非甾體免疫調節小分子抑制劑。除了新聞稿和美國證券交易委員會文件外,我們預計還將在我們的網站和社交媒體賬戶上發佈可能與投資者相關的信息。我們鼓勵投資者在推特和領英上關注我們,訪問我們的網站和/或訂閱電子郵件提醒。
Forward-Looking Statements
前瞻性陳述
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, Kiora's ability to execute on development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-104, KIO-301, KIO-201 and KIO-101, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, the sufficiency of existing cash on hand to fund operations for specific periods, the projected cash runway, the ability to timely complete planned initiatives for 2024, including phase 2 clinical development of KIO-301 and KIO-104, the potential for KIO-301 to be the first treatment options for patients with inherited degenerative diseases like RP, Kiora's plans to further fund development of KIO-104, the potential for KIO-104 to reduce inflammation, the timing of topline results from a Phase 2b trial of KIO-104, the potential for KIO-104 to apply to other retinal inflammatory diseases, and expected trends for research and development and general and administrative spending in 2024. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to satisfy the closing conditions related to the offering ,the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2024 or described in Kiora's other public filings including on Form 10-Q filed with the SEC on May 10, 2024. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.
本新聞稿中的一些聲明是 “前瞻性的”,是根據1995年《私人證券訴訟改革法》的安全港條款作出的。這些 “前瞻性” 陳述包括與Kiora執行開發和商業化工作以及與Kiora開發階段產品(包括 KIO-104、KIO-301、KIO-201 和 KIO-101)相關的其他監管或營銷批准工作的能力以及其成功的陳述,此類批准或成功可能無法及時獲得或實現,或根本無法獲得或取得成功,現有手頭現金足以爲特定時期的運營提供資金,預計的現金流,及時的能力完成 2024 年的計劃計劃,包括 KIO-301 和 KIO-104 的 2 期臨床開發、KIO-301 可能成爲遺傳性退行性疾病(如 RP)患者的首選治療方案、Kiora 進一步資助開發 KIO-104 的計劃、KIO-104 減輕炎症的可能性、KIO-104 2b 期試驗結果的發佈時機、KIO-104 應用於其他視網膜炎性疾病的可能性,以及研發和總體研究的預期趨勢 2024年的行政支出。這些聲明涉及風險和不確定性,可能導致結果與本新聞稿中列出的聲明存在重大差異,包括滿足與發行相關的成交條件的能力、及時進行臨床試驗的能力、市場和其他條件以及在 “風險因素” 標題下描述的某些風險因素,這些風險因素載於Kiora於2024年3月25日向美國證券交易委員會提交的10-K表年度報告或Kiora's中描述的 “風險因素” 標題下描述的某些風險因素其他公開文件,包括向其提交的10-Q表格美國證券交易委員會於2024年5月10日上線。Kiora的業績還可能受到Kiora目前尚未意識到的因素的影響。本新聞稿中的前瞻性陳述僅代表截至本新聞稿發佈之日。除非法律要求,否則Kiora明確表示不承擔任何義務或承諾公開發布此類聲明的任何更新或修訂,以反映其對該聲明的期望的任何變化或任何此類聲明所依據的事件、條件或情況的任何變化。
CONDENSED CONSOLIDATED BALANCE SHEETS
簡明的合併資產負債表
March 31, 2024 (unaudited) |
December 31, 2023 | ||||||
ASSETS | |||||||
Current Assets: | |||||||
Cash and Cash Equivalents | $ | 31,276,330 |
$ | 2,454,684 |
|||
Prepaid Expenses and Other Current Assets | 206,671 |
233,382 |
|||||
Collaboration Receivables | 189,905 |
— |
|||||
Tax Receivables | 1,808,787 |
2,049,965 |
|||||
Total Current Assets | 33,481,693 |
4,738,031 |
|||||
Non-Current Assets: | |
|
|||||
Property and Equipment, Net | 12,918 |
8,065 |
|||||
Restricted Cash | 4,084 |
4,267 |
|||||
Intangible Assets and In-Process R&D, Net | 8,807,600 |
8,813,850 |
|||||
Operating Lease Assets with Right-of-Use | 94,298 |
106,890 |
|||||
Other Assets | 39,414 |
40,767 |
|||||
Total Assets | $ | 42,440,007 |
$ | 13,711,870 |
|||
LIABILITIES AND STOCKHOLDERS' EQUITY | |
|
|||||
Current Liabilities: | |
|
|||||
Accounts Payable | $ | 323,062 |
$ | 206,260 |
|||
Accrued Expenses | 1,222,078 |
1,380,666 |
|||||
Operating Lease Liabilities | 47,851 |
47,069 |
|||||
Total Current Liabilities | 1,592,991 |
1,633,995 |
|||||
Non-Current Liabilities: | |
|
|||||
Contingent Consideration | 5,116,765 |
5,128,959 |
|||||
Deferred Tax Liability | 779,440 |
779,440 |
|||||
Operating Lease Liabilities | 46,448 |
59,822 |
|||||
Total Non-Current Liabilities | 5,942,653 |
5,968,221 |
|||||
Total Liabilities | 7,535,644 |
7,602,216 |
|||||
Commitments and Contingencies (Note 8) | |
|
|||||
Stockholders' Equity: | |
|
|||||
Preferred Stock, $0.01 Par Value: 10,000,000 shares authorized; 3,750 designated Series A, 0 shares issued and outstanding; 10,000 designated Series B, 0 shares issued and outstanding; 10,000 shares designated Series C, 0 shares issued and outstanding; 20,000 shares designated Series D, 7 shares issued and outstanding; 1,280 shares designated Series E, 0 shares issued and outstanding; 3,908 shares designated Series F, 420 issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 4 |
4 |
|||||
Common Stock, $0.01 Par Value: 50,000,000 shares authorized; 26,256,197 and 7,705,640 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 262,584 |
77,078 |
|||||
Additional Paid-In Capital | 168,429,797 |
153,192,228 |
|||||
Accumulated Deficit | (133,523,648) | (146,976,855) | |||||
Accumulated Other Comprehensive Loss | (264,374) | (182,801) | |||||
Total Stockholders' Equity | 34,904,363 |
6,109,654 |
|||||
Total Liabilities and Stockholders' Equity | $ | 42,440,007 |
$ | 13,711,870 |
2024年3月31日 (未經審計) |
2023年12月31日 | ||||||
資產 | |||||||
流動資產: | |||||||
現金和現金等價物 | $ | 31,276,330 |
$ | 2,454,684 |
|||
預付費用和其他流動資產 | 206,671 |
233,382 |
|||||
合作應收賬款 | 189,905 |
— |
|||||
應收稅款 | 1,808,787 |
2,049,965 |
|||||
流動資產總額 | 33,481,693 |
4,738,031 |
|||||
非流動資產: | |
|
|||||
財產和設備,淨額 | 12,918 |
8,065 |
|||||
限制性現金 | 4,084 |
4,267 |
|||||
無形資產和在建研發,淨額 | 8,807,600 |
8,813,850 |
|||||
具有使用權的經營租賃資產 | 94,298 |
106,890 |
|||||
其他資產 | 39,414 |
40,767 |
|||||
總資產 | $ | 42,440,007 |
$ | 13,711,870 |
|||
負債和股東權益 | |
|
|||||
流動負債: | |
|
|||||
應付賬款 | $ | 323,062 |
$ | 206,260 |
|||
應計費用 | 1,222,078 |
1,380,666 |
|||||
經營租賃負債 | 47,851 |
47,069 |
|||||
流動負債總額 | 1,592,991 |
1,633,995 |
|||||
非流動負債: | |
|
|||||
偶然考慮 | 5,116,765 |
5,128,959 |
|||||
遞延所得稅負債 | 779,440 |
779,440 |
|||||
經營租賃負債 | 46,448 |
59,822 |
|||||
非流動負債總額 | 5,942,653 |
5,968,221 |
|||||
負債總額 | 7,535,644 |
7,602,216 |
|||||
承付款項和或有開支(注8) | |
|
|||||
股東權益: | |
|
|||||
優先股,面值0.01美元:授權1,000,000股;指定A系列3,750股,已發行和流通股票;1萬股指定B系列,0股已發行和流通;1萬股指定D系列,7股已發行和流通;1,280股指定E系列,0股已發行和流通;3,908股指定F系列,420股已發行和流通,2024年3月31日和12月31日分別是 2023 年 | 4 |
4 |
|||||
普通股,面值0.01美元:已授權5000萬股;截至2024年3月31日和2023年12月31日已發行和流通的股票分別爲26,256,197和7,705,640股 | 262,584 |
77,078 |
|||||
額外的實收資本 | 168,429,797 |
153,192,228 |
|||||
累計赤字 | (133,523,648) | (146,976,855) | |||||
累計其他綜合虧損 | (264,374) | (182,801) | |||||
股東權益總額 | 34,904,363 |
6,109,654 |
|||||
負債總額和股東權益 | $ | 42,440,007 |
$ | 13,711,870 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE INCOME (LOSS)
(unaudited)
簡明的合併運營報表和
綜合收益(虧損)
(未經審計)
Three Months Ended March 31, | |||||||
2024 | 2023 | ||||||
Revenue: | |||||||
Collaboration Revenue | $ | 16,000,000 |
$ | — |
|||
Total Revenue | 16,000,000 |
— |
|||||
Operating Expenses: | |
|
|||||
General and Administrative | 1,296,441 |
1,269,458 |
|||||
Research and Development | 1,493,659 |
438,283 |
|||||
Change in Fair Value of Contingent Consideration | (12,194) | 208,926 |
|||||
Total Operating Expenses | 2,777,906 |
1,916,667 |
|||||
Operating Income (Loss) | 13,222,094 |
(1,916,667) | |||||
Other Income, Net: | |
|
|||||
Interest Income, Net | 223,047 |
33,465 |
|||||
Other Income, Net | 8,066 |
14,666 |
|||||
Total Other Income, Net | 231,113 |
48,131 |
|||||
Net Income (Loss) | $ | 13,453,207 |
$ | (1,868,536) | |||
Net Income (Loss) per Common Share - Basic |
$ | 0.52 |
$ | (1.00) | |||
Weighted Average Shares Outstanding - Basic |
25,936,163 |
1,863,466 |
|||||
Net Income (Loss) per Common Share - Diluted |
$ | 0.38 |
(1.00) | ||||
Weighted Average Shares Outstanding - Diluted |
35,025,494 | 1,863,466 | |||||
|
|
||||||
Other Comprehensive Income (Loss): | |
|
|||||
Net Income (Loss) | $ | 13,453,207 |
$ | (1,868,536) | |||
Foreign Currency Translation Adjustments | (81,573) | (32,671) | |||||
Comprehensive Income (Loss) | $ | 13,371,634 |
$ | (1,901,207) |
截至3月31日的三個月 | |||||||
2024 | 2023 | ||||||
收入: | |||||||
協作收入 | $ | 16,000,000 |
$ | — |
|||
總收入 | 16,000,000 |
— |
|||||
運營費用: | |
|
|||||
一般和行政 | 1,296,441 |
1,269,458 |
|||||
研究和開發 | 1,493,659 |
438,283 |
|||||
或有對價公允價值的變動 | (12,194) | 208,926 |
|||||
總運營費用 | 2,777,906 |
1,916,667 |
|||||
營業收入(虧損) | 13,222,094 |
(1,916,667) | |||||
其他收入,淨額: | |
|
|||||
利息收入,淨額 | 223,047 |
33,465 |
|||||
其他收入,淨額 | 8,066 |
14,666 |
|||||
其他收入總額,淨額 | 231,113 |
48,131 |
|||||
淨收益(虧損) | $ | 13,453,207 |
$ | (1,868,536) | |||
普通股每股淨收益(虧損)——基本 |
$ | 0.52 |
$ | (1.00) | |||
加權平均流通股數-基本 |
25,936,163 |
1,863,466 |
|||||
普通股每股淨收益(虧損)——攤薄 |
$ | 0.38 |
(1.00) | ||||
加權平均流通股數-攤薄 |
35,025,494 | 1,863,466 | |||||
|
|
||||||
其他綜合收益(虧損): | |
|
|||||
淨收益(虧損) | $ | 13,453,207 |
$ | (1,868,536) | |||
外幣折算調整 | (81,573) | (32,671) | |||||
綜合收益(虧損) | $ | 13,371,634 |
$ | (1,901,207) |
譯文內容由第三人軟體翻譯。